188 related articles for article (PubMed ID: 11377199)
1. Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate.
Davies TG; Tunnah P; Meijer L; Marko D; Eisenbrand G; Endicott JA; Noble ME
Structure; 2001 May; 9(5):389-97. PubMed ID: 11377199
[TBL] [Abstract][Full Text] [Related]
2. Binding of the potential antitumour agent indirubin-5-sulphonate at the inhibitor site of rabbit muscle glycogen phosphorylase b. Comparison with ligand binding to pCDK2-cyclin A complex.
Kosmopoulou MN; Leonidas DD; Chrysina ED; Bischler N; Eisenbrand G; Sakarellos CE; Pauptit R; Oikonomakos NG
Eur J Biochem; 2004 Jun; 271(11):2280-90. PubMed ID: 15153119
[TBL] [Abstract][Full Text] [Related]
3. Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex.
Russo AA; Jeffrey PD; Patten AK; Massagué J; Pavletich NP
Nature; 1996 Jul; 382(6589):325-31. PubMed ID: 8684460
[TBL] [Abstract][Full Text] [Related]
4. Crystal structure of a viral cyclin, a positive regulator of cyclin-dependent kinase 6.
Schulze-Gahmen U; Jung JU; Kim SH
Structure; 1999 Mar; 7(3):245-54. PubMed ID: 10368294
[TBL] [Abstract][Full Text] [Related]
5. Alternative binding modes of an inhibitor to two different kinases.
De Moliner E; Brown NR; Johnson LN
Eur J Biochem; 2003 Aug; 270(15):3174-81. PubMed ID: 12869192
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine.
De Azevedo WF; Leclerc S; Meijer L; Havlicek L; Strnad M; Kim SH
Eur J Biochem; 1997 Jan; 243(1-2):518-26. PubMed ID: 9030780
[TBL] [Abstract][Full Text] [Related]
7. Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity.
Brown NR; Noble ME; Lawrie AM; Morris MC; Tunnah P; Divita G; Johnson LN; Endicott JA
J Biol Chem; 1999 Mar; 274(13):8746-56. PubMed ID: 10085115
[TBL] [Abstract][Full Text] [Related]
8. X-ray crystallographic studies of CDK2, a basis for cyclin-dependent kinase inhibitor design in anti-cancer drug research.
Furet P
Curr Med Chem Anticancer Agents; 2003 Jan; 3(1):15-23. PubMed ID: 12678911
[TBL] [Abstract][Full Text] [Related]
9. Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives.
Gibson AE; Arris CE; Bentley J; Boyle FT; Curtin NJ; Davies TG; Endicott JA; Golding BT; Grant S; Griffin RJ; Jewsbury P; Johnson LN; Mesguiche V; Newell DR; Noble ME; Tucker JA; Whitfield HJ
J Med Chem; 2002 Aug; 45(16):3381-93. PubMed ID: 12139449
[TBL] [Abstract][Full Text] [Related]
10. Specificity determinants of recruitment peptides bound to phospho-CDK2/cyclin A.
Lowe ED; Tews I; Cheng KY; Brown NR; Gul S; Noble ME; Gamblin SJ; Johnson LN
Biochemistry; 2002 Dec; 41(52):15625-34. PubMed ID: 12501191
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex.
Jeffrey PD; Russo AA; Polyak K; Gibbs E; Hurwitz J; Massagué J; Pavletich NP
Nature; 1995 Jul; 376(6538):313-20. PubMed ID: 7630397
[TBL] [Abstract][Full Text] [Related]
12. Kinetic mechanism of activation of the Cdk2/cyclin A complex. Key role of the C-lobe of the Cdk.
Morris MC; Gondeau C; Tainer JA; Divita G
J Biol Chem; 2002 Jun; 277(26):23847-53. PubMed ID: 11959850
[TBL] [Abstract][Full Text] [Related]
13. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases.
Brown NR; Noble ME; Endicott JA; Johnson LN
Nat Cell Biol; 1999 Nov; 1(7):438-43. PubMed ID: 10559988
[TBL] [Abstract][Full Text] [Related]
14. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.
De Azevedo WF; Mueller-Dieckmann HJ; Schulze-Gahmen U; Worland PJ; Sausville E; Kim SH
Proc Natl Acad Sci U S A; 1996 Apr; 93(7):2735-40. PubMed ID: 8610110
[TBL] [Abstract][Full Text] [Related]
15. Structural studies on phospho-CDK2/cyclin A bound to nitrate, a transition state analogue: implications for the protein kinase mechanism.
Cook A; Lowe ED; Chrysina ED; Skamnaki VT; Oikonomakos NG; Johnson LN
Biochemistry; 2002 Jun; 41(23):7301-11. PubMed ID: 12044161
[TBL] [Abstract][Full Text] [Related]
16. Peptide inhibitors of CDK2-cyclin A that target the cyclin recruitment-site: structural variants of the C-terminal Phe.
Atkinson GE; Cowan A; McInnes C; Zheleva DI; Fischer PM; Chan WC
Bioorg Med Chem Lett; 2002 Sep; 12(18):2501-5. PubMed ID: 12182847
[TBL] [Abstract][Full Text] [Related]
17. Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: comparative molecular dynamics simulation studies of CDK2 and CDK4.
Park H; Yeom MS; Lee S
Chembiochem; 2004 Dec; 5(12):1662-72. PubMed ID: 15505811
[TBL] [Abstract][Full Text] [Related]
18. Structural basis of cyclin-dependent kinase activation by phosphorylation.
Russo AA; Jeffrey PD; Pavletich NP
Nat Struct Biol; 1996 Aug; 3(8):696-700. PubMed ID: 8756328
[TBL] [Abstract][Full Text] [Related]
19. Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2.
Otyepka M; Krystof V; Havlícek L; Siglerová V; Strnad M; Koca J
J Med Chem; 2000 Jun; 43(13):2506-13. PubMed ID: 10891109
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure of a gamma-herpesvirus cyclin-cdk complex.
Card GL; Knowles P; Laman H; Jones N; McDonald NQ
EMBO J; 2000 Jun; 19(12):2877-88. PubMed ID: 10856233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
